Group 1 - The core point of the article is that Zhongguancun announced the acquisition of a utility model patent for a sodium sulfanilate preparation mixing device by its subsidiary, Shandong Huasu Pharmaceutical Co., Ltd. [2] - In the fiscal year 2024, Zhongguancun's revenue composition is as follows: 74.96% from biomedicine, 17.48% from concrete, 4.94% from elderly health, and 2.62% from other sectors [2]